New Cross-linked Hyaluronan Gel to Prevent Adhesion After USG-MVA: RCT

Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 28, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new gel called NCH (New Cross-linked Hyaluronan Gel) to see if it can help prevent the development of intrauterine adhesions (scar tissue in the uterus) after a specific procedure for treating early pregnancy loss. The study will compare two groups of women: one group receiving the NCH gel and another group that does not. Researchers will look at how effective the gel is in preventing these adhesions, any side effects it might cause, and how it affects women's menstrual cycles and chances of future pregnancies.

To participate in the trial, women must be at least 18 years old and should not have a history of intrauterine adhesions or certain previous surgeries related to their uterus. Participants will need to give their consent and understand what the study involves. If you choose to take part, you can expect to be monitored for any side effects and to have follow-up assessments to track your recovery and reproductive health. This trial is currently recruiting participants, so if you meet the criteria and are interested, you can reach out for more information.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women 18 years old or above
• • No previous history of IUA/ Asherman's syndrome
• • No previous surgical history of EVA or dilatation or curettage or surgical termination of pregnancy or caesarean section
• • No previous history of therapeutic hysteroscopic surgeries
• • Voluntary informed consent and understanding of study
• Exclusion Criteria:
• • previous therapeutic hysteroscopic procedures (e.g. endometrial ablation, removal of fibroids or polyps, surgical correction of congenital uterine anomalies or adhesiolysis)
• • suspicion of molar pregnancy
• • genital tract malformation
• • suspicion of active infection or genital tract malignancy or genital tuberculosis
• • abnormal blood coagulation
• • inability to tolerate pelvic examination known
• • suspected intolerance of hypersensitivity to NCH gel or its derivatives
• • patient refusal